Background: This article provides a summary of the 2013 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report (available at http://www.era-edta-reg.org), with a focus on patients with diabetes mellitus (DM) as the cause of end-stage renal disease (ESRD).
Introduction
The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry collects data on renal replacement therapy (RRT) for end-stage renal disease (ESRD) via national and regional renal registries in Europe and from countries bordering the Mediterranean Sea. Each year an annual report is produced, presenting an overview of the incidence and prevalence of RRT, kidney transplant activity and the survival of patients on RRT in Europe. With this article, we aim to provide a summary of the 2013 Annual Report of the ERA-EDTA Registry [1] . Both the Annual Report and slides summarizing the Annual Report are available at http://www.era-edta-reg.org. This article specifically focuses on the most common cause of ESRD in the Western world: diabetes mellitus (DM).
Methods
In 2015, the ERA-EDTA Registry received 2013 data from 49 national and regional renal registries in 34 countries in Europe and those bordering the Mediterranean Sea. The majority of renal registries (31 of 49) contributed individual patient data, whereas the other 18 renal registries contributed aggregated data ( Figure 1) .
While a standard Microsoft Excel template was used for the collection of aggregated data, the individual patient data were received in different formats, including SPSS, Microsoft Excel and SAS. Extensive data checking was performed and the data were converted to a standard format in order to be stored in a relational database. After data analysis, the results were checked by the participating renal registries. All registry-specific results in the ERA-EDTA Registry Annual Report were approved by the registries before publication.
Mid-year population data for the contributing countries/ regions were received from Eurostat (http://ec.europa.eu/eurostat), the national bureau of statistics or the renal registry.
The incidence of RRT was defined as the number of patients starting RRT in one year (2013) and the prevalence of RRT as the number of patients alive and receiving RRT on 31 December 2013. Incidence and prevalence per million population ( pmp) were calculated by dividing the observed count by the mid-year population. Time trends of the incidence rates were analysed using Joinpoint regression, with the trends presented as annual percentage change (APC) [2, 3] .
Patient survival on RRT, on dialysis and following kidney transplantation was analysed using data from renal registries providing individual patient data for the period 2004-13. A detailed description of the survival methods is given in the Appendix.
Patients were included in the DM subgroup if they were registered as having DM type 1 or type 2 as the cause of ESRD (ERA-EDTA primary renal disease 1995 codes 80 or 81 or ERA-EDTA primary renal disease 2012 codes 2316, 2328, 2337 or 2344 A summary of the 2013 ERA-EDTA Registry Annual Report | 459
. As information on DM as comorbidity is not routinely collected by the ERA-EDTA Registry, this article only focuses on DM as the cause of ESRD.
Statistical methods
Within this article, patient survival on RRT and following kidney transplantation was analysed using the Kaplan-Meier method and Cox proportional hazards regression. For dialysis patients, kidney transplantation is an event that competes with death. Therefore, we used the cumulative incidence competing risk method for the estimation of the unadjusted cause-specific death probabilities, and the Fine and Gray method for the adjusted cause-specific death probabilities [7] . For the calculation of patient survival on RRT and on dialysis, the date of RRT initiation was the starting point and death was the event studied. Censored observations were recovery of renal function, loss to follow-up and end of the follow-up period (31 December 2013). For analysis of patient survival following kidney transplantation, the date of the first kidney transplant was defined as the first day of follow-up and death was the event studied. Reasons for censoring were loss to follow-up and end of the follow-up period. RRT and dialysis survival probabilities were adjusted for fixed values for age (60 years), gender (60% men) and the cause of ESRD distribution (20% DM, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes of ESRD). Transplantation survival probabilities were adjusted for the following values: age 45 years, 60% men, 10% DM, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other causes of ESRD. For the adjusted survival probabilities of the DM subgroup, the corresponding fixed values were used with the exception of the cause of ESRD distribution.
Results
For the majority of renal registries contributing data to the ERA-EDTA Registry, the coverage of the population was 100%, with the exception of Croatia (80%), Latvia (80%), Serbia (94%), Switzerland (94%), Spain (95%), Poland (95%), Georgia (96%), Bulgaria (97%), Czech Republic (98%) and Romania (99%). The total population covered by the participating registries comprised 650 million people. The proportion of the European population covered by the ERA-EDTA Registry in 2013 was 73.6%. A list of the European countries with available data and those without is provided in the Appendix.
Incidence of RRT in 2013
In 2013, a total of 72 933 patients started RRT for ESRD in all the registries reporting to the ERA-EDTA Registry, resulting in an 
overall incidence of 112 pmp (Figure 2 ). For countries/regions providing individual patient data (left panel), the overall incidence at Day 1 was 135 pmp, while it was 98 pmp for countries providing aggregated data (right panel). The lowest incidence rates were found in Montenegro (27 pmp), Ukraine (30 pmp) and Russia (50 pmp), whereas the highest rates were observed in The category HD also includes haemofiltration and haemodiafiltration. When cells are left empty, the data are unavailable.
HD: haemodialysis, PD: peritoneal dialysis, Tx: kidney transplant.
a
The incidence at Day 91 is based on patients who started RRT in the first 9 months of 2013.
Greece (216 pmp) and both parts of Belgium (Dutch-speaking part: 187 pmp, French-speaking part: 183 pmp). Figure 2 also shows the contribution of DM as the cause of ESRD to the incidence of RRT. Overall, patients who had DM as the cause of ESRD comprised 24% of the incident patients (26 pmp). For 48% of those patients, the type of DM was unknown (12 pmp), while 12% (3 pmp) had DM type 1 and 40% (10 pmp) had DM type 2. Among countries/regions whose registries provide individual patient data, the incidence of RRT for ESRD secondary to DM ranged between 12 pmp in Iceland and 58 pmp in Greece. However, in countries with a high proportion of patients with an unknown or missing cause of ESRD, the proportion of patients with DM as the cause of ESRD may be underestimated, as DM may be the cause of ESRD in some of these patients. For this reason, we also report the incidence of RRT for ESRD due to unknown or missing causes of ESRD, which varied widely between 0 pmp in Estonia and 73 pmp in Greece. Countries providing aggregated data showed a greater difference in the incidence of RRT secondary to DM, ranging from 5 pmp in Ukraine to 83 pmp in Israel. In general, countries/regions with a high overall incidence of RRT also had a high incidence of RRT for ESRD secondary to DM. Table 1 shows the unadjusted incidence of RRT pmp on Day 91 after the onset of RRT by established treatment modality (haemodialysis, peritoneal dialysis and kidney transplantation). Overall, most patients were treated with haemodialysis (99 pmp in renal registries providing individual patient data and 137 pmp in those providing aggregated data), whereas the incidence of peritoneal dialysis was much lower (19 and 10 pmp, respectively). The incidence of kidney transplantation on Day 91 was highest in The Netherlands (17 pmp) and Norway (15 pmp), whereas it was lowest in Bosnia and Herzegovina and the Spanish region of Extremadura (0 pmp in both cases). Table 2 presents the percentages of established treatment modalities on Day 91 after the start of Herzegovina  97  3  0  0  97  3  0  0  96  4  0  0  97  3  0  0  Denmark  60  31  8  0  67  30  3  0  60  28  12  0  55  41  4  1  Estonia  73  20  6  0  56  38  6  0  78  16  6  0  0  0  0  0  Finland  67  32  1  0  66  34  0  0  66  33  2  0  75  25  0  0  France  83  12  4  0  88  10  2  0  82  12  5  0  82  14  4  0  Greece  93  7  0  0  91  9  0  0  93  7  0  0  93  6  0  0  Iceland  42  46  13  0  50  25  25  0  44  44  11  0  0  100  0  0  Norway  62  23  15  0  69  17  14  0  60  24  16  0  79  21  0  0  Romania  94  5  1  0  94  5  0  0  93  5  2  0  94  6  0  0  Serbia  85  13  2  0  78  20  1  0  89  9  2  0  82  17  1  0  Slovenia  89  10  2  0  89  11  0  0  85  12  3  0  98  2  0  0  Spain  Andalusia  78  17  4  0  83  15  2  0  74  21  5  0  84  12  5  0  Aragon  77  21  2  0  81  17  2  0  71  26  3  0  87  13  0  0  Asturias   a   67  31  2  0  45  55  0  0  71  28  1  0  90  0  10  0  Basque country  63  28  9  0  72  26  2  0  65  25  10  0  44  42 A summary of the 2013 ERA-EDTA Registry Annual Report | 463 RRT for all patients, for patients with DM, for patients with other causes of ESRD and for patients with an unknown cause of ESRD. Patients with DM were more often treated with any type of dialysis on Day 91 after the start of RRT than patients with other causes of ESRD (98 versus 93%), while they were less often transplanted (2 versus 7%).
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Patients with DM as the cause of ESRD comprised 17% of the prevalent patients (122 pmp). For 54% of these patients, the type of DM was unknown (66 pmp), while 14% (18 pmp) had DM type 1 and 31% (38 pmp) had DM type 2. In countries/regions with registries providing individual patient data, the overall prevalence of RRT for ESRD secondary to DM was 159 pmp, ranging between 74 pmp in Iceland and 219 pmp in Greece. Tables 3  and 4 present the prevalence by treatment modality (haemodialysis, peritoneal dialysis and kidney transplantation) on 31 December 2013 ( pmp and as percentage). In countries/regions with registries providing individual patient data, most prevalent patients were receiving haemodialysis, closely followed by those with a functioning graft. In countries with registries providing aggregated data, the great majority of the patients were receiving haemodialysis. Table 4 shows that in case of patients with DM as the cause of ESRD, only four registries reported ≥50% of patients living with a functioning graft. In contrast, for other causes of ESRD, the vast majority of the registries reported that more than half of the patients had a functioning graft.
Kidney transplants performed in 2013 Figure 5 shows the kidney transplant rate in 2013 for countries/regions whose registries provide individual patient data and for countries whose registries provide aggregated patient data, by donor type. Overall, 19 426 kidney transplantations were performed (30 pmp), of which 6002 (9 pmp) transplants came from living donors, 13 207 (20 pmp) from deceased donors and 217 (0.3 pmp) from an unknown donor source. The three Spanish regions-Cantabria (104 pmp), Basque country (75 pmp) and Catalonia (71 pmp)-had the highest kidney transplant rates, while Ukraine (3 pmp), Albania (3 pmp) and Russia (7 pmp) showed the lowest rates. The highest living donor kidney transplant rates were found in The Netherlands (31 pmp), Turkey (31 pmp) and Cyprus (27 pmp).
Patient survival
Survival analyses included data from 22 registries in 11 countries, which provided individual patient data for the period of 2004-11. 
Discussion
This summary of the 2013 ERA-EDTA Registry Annual Report includes data from 49 national and regional renal registries in 34 countries in Europe and bordering the Mediterranean Sea, with a special focus on patients receiving RRT for ESRD secondary to DM.
Both the overall incidence of RRT for ESRD and the incidence of RRT for ESRD secondary to DM were substantially lower in Europe than in the USA [4] . However, even in Europe and among countries bordering the Mediterranean Sea, there were notable differences in the incidence of RRT for ESRD secondary to DM. This variation may be explained in part by differences in the prevalence of DM within the general population [5] , differences in preventive measures, such as lifestyle advice and the use of renoprotective medication, and differences in macroeconomic factors and nephrology services [6] . It should be noted that this variation may also be influenced by discrepancies in the proportion of patients coded with a missing or unknown cause of ESRD. A summary of the 2013 ERA-EDTA Registry Annual Report | 467
Nevertheless, in view of the ongoing epidemic of DM in Western societies [5] , it is remarkable that both in Europe and in the USA, the rise in the incidence of RRT for ESRD secondary to DM appears to have subsided. Although patients receiving RRT for ESRD secondary to DM were less likely to receive a kidney transplant and had worse survival compared with the overall group, their survival seems to be improving with time.
In conclusion, we have shown encouraging results for patients receiving RRT for ESRD secondary to DM. This suggests that advances in health care have been effective with regard to the prevention and management of ESRD secondary to DM.
